Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:55 AM
Ignite Modification Date:
2025-12-25 @ 2:55 AM
NCT ID:
NCT01918033
Eligibility Criteria:
Inclusion Criteria:
* Diagnosed with perennial allergic rhinitis
* Outpatient.
Exclusion Criteria:
* Lower respiratory tract infection or nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.)
* Coexisting infections or systemic mycosis for which there are no effective antibiotics
* Asthma complication under treatment
* Nasal septum ulcers, nasal surgery, or nasal trauma, which has not healed
* Vasomotor rhinitis or eosinophilic rhinitis
* Nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug
* History of hypersensitivity to antihistamines or study drug
* Currently receiving treatment with another investigational drug or has received an investigational drug in the past 3 months
* Has started specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapies within 90 days (3 months) before the day of obtaining informed consent
* Severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor
* History of malignancy or clinically important hematological disorder
* History of severe drug allergy (e.g., anaphylactoid reaction).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Study:
NCT01918033
Study Brief:
Protocol Section:
NCT01918033